Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Spinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Risk of Major Adverse Cardiovascular Events, Mortality, Amputation, Infection and Suicide: Real-World Evidence
Alexander Henney, Bernhard Frank, David R. Riley, Matthew Anson, Jamie Burgess, Gema Hernández, Professor Gregory Lip, Rayaz A. Malik, Solomon Tesfaye, Daniel J. Cuthbertson, Uazman Alam (2025). Spinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Risk of Major Adverse Cardiovascular Events, Mortality, Amputation, Infection and Suicide: Real-World Evidence. , DOI: https://doi.org/10.2139/ssrn.5114592.
Preprint17 days agoSpinal cord stimulation for the treatment of painful diabetic neuropathy and risk of major adverse cardiovascular events, mortality, amputation, infection and suicide: a retrospective cohort study
Alex E. Henney, Bernhard Frank, David R. Riley, Matthew Anson, Jamie Burgess, Gema Hernadez, Professor Gregory Lip, Rayaz A. Malik, Solomon Tesfaye, Daniel J. Cuthbertson, Uazman Alam (2025). Spinal cord stimulation for the treatment of painful diabetic neuropathy and risk of major adverse cardiovascular events, mortality, amputation, infection and suicide: a retrospective cohort study. , 89, DOI: https://doi.org/10.1016/j.eclinm.2025.103489.
Article17 days agoCardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis
Jonathan Y. M. Lai, David R. Riley, Matthew Anson, Alex E. Henney, Daniel J. Cuthbertson, Gema Hernadez, Philip Austin, Professor Gregory Lip, Sizheng Steven Zhao, Timothy L. Jackson, Katarzyna Nabrdalik, Uazman Alam (2024). Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis. , 15(4), DOI: https://doi.org/10.1007/s13300-024-01544-3.
Article17 days agoAll‐cause mortality and cardiovascular outcomes with <scp>sodium‐glucose</scp> Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
David R. Riley, Hani Essa, Philip Austin, Frank Preston, Isatu Kargbo, Gema Hernández, Ramandeep Ghuman, Daniel J. Cuthbertson, Professor Gregory Lip, Uazman Alam (2023). All‐cause mortality and cardiovascular outcomes with <scp>sodium‐glucose</scp> Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes. , 25(10), DOI: https://doi.org/10.1111/dom.15185.
Article17 days agoAuthor response for "All‐cause mortality and cardiovascular outcomes with <scp>sodium‐glucose</scp> Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes"
David R. Riley, Hani Essa, Philip Austin, Frank Preston, Isatu Kargbo, Gema Hernández, Ramandeep Ghuman, Daniel J. Cuthbertson, Professor Gregory Lip, Uazman Alam (2023). Author response for "All‐cause mortality and cardiovascular outcomes with <scp>sodium‐glucose</scp> Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes". , DOI: https://doi.org/10.1111/dom.15185/v3/response1.
Preprint17 days ago